Sleep & Obesity

Sleep loss and sleep apnea drive obesity and complicate management with major recent trial readouts. The session covers OSA-obesity bidirectionality and the metabolic consequences, GLP-1 effect on OSA (SURMOUNT-OSA trial results showing AHI reduction), sleep duration and weight epidemiology, shift-work and metabolic risk, sleep restriction and food intake, and OSA screening pathways in obesity clinics. Discussion addresses hypoglossal nerve stimulation (Inspire) as alternative to CPAP, central sleep apnea in obesity-hypoventilation syndrome, the comparison of pharmacotherapy vs CPAP vs MAD for OSA, the role of sleep hygiene in weight management, and emerging sleep-targeted obesity pharmacotherapy.